Thursday, May 13, 2021
News
NEWS HOME
»
PRN INDIA
Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial
  SocialTwist Tell-a-Friend  
   

Data presented at ENDO 2021 demonstrate clinically relevant weight loss, without weight regain, in people treated with semaglutide 2.4 mg vs placebo in combination with lifestyle intervention.

BAGSVÆRD, Denmark, March 23, 2021 /PRNewswire/ -- New results from the STEP phase 3a clinical trial programme demonstrated weight loss with investigational treatment of once-weekly subcutaneous semaglutide 2.4 mg versus placebo. In the STEP 4 trial, study participants who reached the maintenance dose of semaglutide 2.4 mg during a 20-week run-in period were randomised to either continue treatment with semaglutide 2.4 mg or switch to placebo for 48 weeks.(1) The full results of the STEP 4 trial were presented today at the virtual Endocrine Society (ENDO) 2021 Annual Meeting and published in the Journal of the American Medical Association.

"For people with obesity, maintaining weight loss in the long term is challenging as both physiological and hormonal changes that occur following an initial weight loss can lead to weight regain. These changes, known as metabolic adaptation, result in lasting increased levels of hunger and desire to eat while reducing energy expenditure," said Dr Domenica Rubino, lead investigator of the STEP 4 trial and Director of Washington Center for Weight Management and Research. "Like any other chronic disease, obesity requires a long-term, individualised approach to care, inclusive of medication and lifestyle components."

Following the 20-week run-in period, people who continued treatment with semaglutide 2.4 mg for an additional 48 weeks continued to lose weight with a statistically significant additional mean weight loss of 7.9% (1) (8.8% for the trial product estimand (2)) from week 20 to week 68. People who were switched to placebo following the 20-week run-in period regained 6.9% (1) of their body weight from week 20 to 68 (6.5% for the trial product estimand (2)). The estimated treatment difference [ETD] for the treatment policy estimand was -14.8% (95% confidence interval [CI]: -16.0, -13.5; p<0.0001). People who stayed on semaglutide 2.4 mg throughout the entire 68-week trial achieved a total weight loss of 17.4% (1) (18.2% for the trial product estimand (2)). Both treatment groups followed a reduced-calorie diet and increased physical activity programme throughout the study.(1)

"Obesity is a chronic disease that requires ongoing management and the results from STEP 4 trial strengthens the evidence around the potential of semaglutide 2.4 mg to transform the medical management of obesity," said Martin Holst Lange, executive vice president, Development at Novo Nordisk. "Millions of people living with obesity are in need of additional treatment options to help them lose weight and keep it off. The results from STEP 4 show that to sustain weight loss it is important to maintain treatment and that semaglutide 2.4 mg has the potential to offer sustained weight loss of more than 17% after 68 weeks of treatment."  

The semaglutide 2.4 mg safety profile is in line with observations seen previously with GLP-1 receptor agonists. It is generally well-tolerated, and the most common adverse events among people treated with semaglutide 2.4 mg were gastrointestinal events.(1)

About STEP 4 and the STEP clinical trial programme

STEP 4 was a 68-week phase 3a randomised, double-blind, multicentre, placebo-controlled trial that compared the safety and efficacy of once-weekly subcutaneous semaglutide 2.4 mg versus placebo on change in body weight. The trial was designed to assess the effect of continuing versus discontinuing semaglutide 2.4 mg in adults with obesity (BMI 30 kg/m2), or overweight (BMI 27 kg/m2) with at least one weight-related comorbidity and without type 2 diabetes (HbA1c <6.5%). During the 20-week run-in period (Week 0 to Week 20), participants were treated with semaglutide (16 weeks escalation, followed by 4 weeks at the target dose) as an adjunct to lifestyle intervention (–500 kcal/day diet together with 150 minutes/week of physical activity). Following the run-in period, the 803 people who reached the maintenance dose of semaglutide (2.4 mg) reduced their mean body weight from 107.2 kg (Week 0) to 96.1 kg (Week 20) and were randomised (in a 2:1 ratio) to continue treatment with semaglutide 2.4 mg or switch to placebo for a further 48 weeks (Week 20 to Week 68) with lifestyle intervention.(2)

The primary endpoint of the trial was the percentage change in body weight from randomisation (Week 20) to the end of treatment (Week 68). Confirmatory secondary endpoints included change in waist circumference, systolic blood pressure, and physical functioning score on the 36-item Short Form Survey (SF-36), assessed from randomisation (Week 20) to the end of treatment (Week 68). Supportive secondary endpoints included percent change in body weight from baseline (Week 0) to the end of treatment (Week 68).(2)  

STEP (Semaglutide Treatment Effect in People with obesity) is a phase 3 clinical development programme with once-weekly subcutaneous semaglutide 2.4 mg in obesity. The global clinical phase 3a programme consists of four trials and has enrolled approximately 4,500 adults with overweight or obesity.(3)

About subcutaneous semaglutide 2.4 mg for weight management

Once-weekly semaglutide 2.4 mg is under investigation for chronic weight management and not yet approved for people with obesity. It is currently under regulatory review in several countries, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Semaglutide is an analogue of the human glucagon-like peptide-1 (GLP-1) hormone, with 94% similarity to the native human GLP-1 molecule. (4,5)  It induces weight loss by reducing hunger, increasing feelings of fullness and thereby helping people eat less and reduce their food cravings.(4)

About obesity

Obesity is a chronic disease that requires long-term management.(6,7) It is associated with many serious health complications and decreased life expectancy.(8,9) Obesity-related complications are numerous and include type 2 diabetes,(7) heart disease,(7)  obstructive sleep apnoea,(10) non-alcoholic fatty liver disease(11) and certain types of cancer.(12) The current COVID-19 pandemic has highlighted that obesity also increases the risk for severe illness and hospitalisation due to COVID-19.(13,14)  

The global increase in the prevalence of obesity is a public health issue that has severe cost implications to healthcare systems. In 2016, 13% of adults, or approximately 650 million adults, were living with obesity worldwide.(15)  

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.

References:

  1. Domenica R, Abrahamsson N, et al. Weight loss maintenance with once-weekly semaglutide 2.4 mg in adults with overweight or obesity reaching maintenance dose. Presented at ENDO Annual Meeting. March 20-23, 2021.
  2. Warkentin LM, Das D, Majumdar SR, et al. The effect of weight loss on health-related quality of life: systematic review and meta-analysis of randomized trials. Obes Rev. 2014; 15:169–182.
  3. Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020; 28:1050-1061.
  4. Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017; 19:1242-1251.
  5. Lau J, Bloch P, Schaffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015; 58:7370-7380.
  6. Wadden TA, et al. Intensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled Trial. Obesity 2019;21:75–86.
  7. WHO. Obesity: Preventing and managing the global epidemic. Available at: http://www.who.int/iris/handle/10665/42330 Last accessed: March 2021.
  8. Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med. 2003; 138:24-32.
  9. Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009; 9:88.
  10. Gami AS, Caples SM and Somers VK. Obesity and obstructive sleep apnea. Endocrinology and Metabolism Clinics of North America. 2003; 32:869-894.
  11. Vernon G, Baranova A and Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011; 34:274-285.
  12. Whitlock G, Lewington S, Sherliker P, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009; 373:1083–1096.
  13. Finer N, Garnett SP and Bruun JM. COVID-19 and obesity. Clin Obes. 2020; 10:e12365.
  14. Ryan DH, Ravussin E and Heymsfield S. COVID 19 and the Patient with Obesity - The Editors Speak Out. Obesity (Silver Spring). 2020; 28:847.
  15. Durrer Schutz D, Busetto L, Dicker D, et al. European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care. Obes Facts. 2019; 12:40-66.

 

(1)                Based on the treatment policy estimand (primary statistical approach): treatment effect regardless of treatment adherence or initiation of other anti-obesity therapies

(2)               Based on the trial product estimand (secondary statistical approach): treatment effect if all people adhered to treatment and did not initiate other anti-obesity therapies

 

More News by PR Newswire India

Damm and Ball launch world's first Aluminium Stewardship Initiative certified beverage cans

LimaCorporate And HSS Partner To Open First Provider-based Design And 3D Printing Center For Complex Joint Reconstruction Surgery

WhiteHat Jr.'s search for Tech Leaders steered by Purple Quarter

Ampersand Group successfully concludes digital intervention, development across Nashik Anganwadis

Siply Launches Affordable Gold Savings Scheme with High Returns for the Masses

Glenmark Pharmaceuticals receives ANDA approval for Chlorpromazine Hydrochloride Tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity

Aavishkaar Group dedicates its Group Impact Report 2020 to 55 Million women leaders in its ecosystem

Feedback plc: International expansion with appointment of two industry specialists in India

LexisNexis Risk Solutions Study Reveals Financial Crime Compliance Costs Across Asia-Pacific Region Increased 20.6% Year Over Year

Eight Manga Artists' Works Exhibited at Kansai Airport Starting March 20

Asia Pacific banks are ready to take advantage of truly digital cores - delivering competitive advantages beyond cost

Citizenship by Investment Funded Real Estate Developments Will Bolster Dominica's Tourism Offering

Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial

Cleaner, Clearer Pool and Spa Water

Gastops celebrates 3,500th engine sensor delivery for F-35 Lightning II

Amazfit T-Rex Pro: A Tough Military-grade Smartwatch with Endurance to Match Your Own and up to 18 Days' Battery Life[1]

Rugged Military-Grade Smartwatch is the Ultimate Partner for Challenging Military-Grade Obstacle Course, Amazfit Partners with Spartan

Meitra Hospital Redefines its Brand Identity

Second Star-studded Hank's Home Game Sees Jokes, Jibes and Showdowns in the Name of Charity at PokerStars.net

Goa Introduces Olectra Electric Buses in its fleet

Haier's Healthy Air Conditioners Rank Number One in Three Prestigious Euromonitor International Categories

AeC Lauded by Frost & Sullivan for Employing a Mix of Technology and Human Expertise to further strengthen its position in the Brazilian Customer Experience Outsourcing Market

Pharmactive Earns Acclaim from Frost & Sullivan for Helping People Improve their Cognitive Functions with its Saffron-based Ingredient, Affron®

HPE Lauded by Frost & Sullivan for Lowering the Risk of 5G Deployments

Uptake Recognized by Frost & Sullivan for Its Predictive Modeling Solutions for Medium-to-heavy-duty Vehicles

Brands are Redefining the Customer Experience by Adopting a Digital-first Approach

IIIT Hyderabad Announces M.Tech Program in Product Design and Management

U.S. Polo Assn. to Sponsor the Annual Lexus International Gay Polo Tournament Celebrating the Gay Polo League

Eagle Eye and Neptune Retail Solutions Enable a Better Digital Coupon Experience for Southeastern Grocers' Shoppers

Sinopec Signs Long-term Liquefied Natural Gas Deal of 2 Million Tons per Annum with Qatar Petroleum

Byogy Commissions Sustainable Low Carbon Jet Fuel Plant in Japan Advancing 'Alcohol to Jet' to Zero Carbon

Xinhua Silk Road: Changsha Economic and Technological Development Zone in C. China's Hunan unveils multiple measures to attract talents worldwide

AWE 2021: Haier Smart Home Brings Revolutionary Living Experience Empowered by its Smart Home Solution

New Research Reveals Top Investment Migration Program Options for HNWIs Seeking Health Security

V-Marc India Limited Initial Public Offering of Equity Shares opening on Thursday, March 25, 2021

Digital-First Tylko Raises €22 Million in Series C as Part of Its Commitment to Set New Standards in the Furniture Industry

Life Cycle Analysis of Corbion's AlgaPrime™ DHA Validates Lower Carbon Footprint Compared to Traditional Sources of Fish Oil

Logiq Partners with Comviva to Offer Digital Wallet and Payment Services to Millions of Mobile Users Across Indonesia

Diluent or Immuno-Reagent solutions for your diagnostic testing kits (Covid, Flu, etc.)

oneZero releases Algorithmic Pricing Module to give institutional clients even greater control

World Class Cocktail Festival: 2021 Homecoming

On World Water Day 2021, Sensus unveils exclusive whitepaper - 'Smart Cities need Smart Water'

Hexaware Technologies is Great Place to Work - certified

Ghodawat Consumer Earns a Prestigious Award; Bags 'India's Most Admirable Brand' Recognition

Glenmark Pharmaceuticals receives ANDA approval for Diltiazem Hydrochloride Extended-Release Capsules USP, 60 mg, 90 mg, and 120 mg: Granted competitive generic therapy (CGT) designation and is eligible for 180 days of CGT exclusivity

UST Provides Online Retail Platform Solution for UNIQLO India to Launch 'Shop From Home' Service

IAS Launches First Industry-Wide Digital Ad Verification Training Program

Bruce Lee's lost passion project 'The Silent Flute' to be produced by entrepreneur Jason Kothari

WZCC announces an exciting webinar with Mr. Piruz Khambatta, Chairman of Rasna, Hon. Consul General South Korea, Director GNFC, Chairman Rasna Foundation and Founder Trustee Areez Khambatta Benevolent Trust

HarperCollins is delighted to announce: Everything the Light Touches by Janice Pariat, publishing from Fourth Estate in October 2022

Crypto Liquidity Platform Black Ocean Opens Customer Whitelist

PathogenDx Applauded by Frost & Sullivan for Its Ultra-rapid COVID-19 Testing Platform, DetectX-Rv Test

Global Semiconductor Materials Market Sets New High of $55.3 Billion With 5% Expansion in 2020, SEMI Reports

Catalyst Welcomes Accenture CEO Julie Sweet As New Board Chair

Frost & Sullivan Opens Nominations for Itron Excellence in Resourcefulness Awards

Squirrels Boosts AirPlay, Miracast and Google Cast With All-New Reflector 4

Stockholm International Water Institute: Freshwater Thought Leader Sandra Postel awarded 2021 Stockholm Water Prize

Astral Foundation helps Hiwali get its first water pipeline after independence

Sirtex Medical announces new SIR-Spheres® DOORwaY-90 Study: The first prospective multicenter U.S.-based trial for registration as first-line treatment for hepatocellular carcinoma

Frost & Sullivan Experts Analyze Regional Tactics for Water and Sanitation for All by 2030

NEC Earns Acclaim from Frost & Sullivan for Adopting a Vector-based Approach to High-performance Computing with its SX-Aurora TSUBASA

Voyager Labs Partners with Microsoft to Provide AI SaaS Investigation Platforms to Empower Public Safety

Global Energy Prize 2021 - record number of participating countries

RedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in Switzerland

Summer Gold Coin Offer begins on KhelPlay Rummy

Planet Water Foundation Brings Life-Changing Access to Clean Drinking Water to Communities Across 5 Countries as Part of World Water Day Activation

RDIF and Virchow Biotech partner for production of Sputnik V vaccine in India

Sonata Software to tap the Customer Experience (CX) Market to fuel growth

Mana Projects Celebrating 21 Years of Real Estate Excellence

Avaya Acclaimed by Frost & Sullivan for Seizing Growth Opportunities with its Robust Portfolio of Intelligent Contact Center Solutions

Glenmark and Bausch Health join together to commercialize RYALTRIS ™ nasal spray in Canada

AVEVA and OSIsoft Combine to Unlock the Potential of Data to Drive Increased Performance for Industrial Organizations

Xinhua Silk Road: Nanjing Jiangbei New Area invites global partners to jointly promote dev. of life and health industry

Zalando Launches Spring Campaign to Laud Society's Champions & Celebrate Their Values

Hexaware Technologies Announces a Work Integrated Learning Program for Freshers

Empuls by Xoxoday integrates with Slack

India's Top Student Volunteers Felicitated At The 11th Annual Pramerica Spirit of Community Awards

Rajshri Entertainment to Make Its Wellness Content Available on Gaana as Podcasts

Plintron powers a unique educational initiative by SmartCentric

IBM Launches Fourth Annual Call for Code Global Challenge to Tackle Existential Threat of Climate Change

Product Analytics is the Number One Measurement of Digital Success, New Report By Harvard Business Review Analytic Services Sponsored by Amplitude Shows

SVKM's NMIMS Invites Applications for Post-Graduate Pharmacy Programs

PrettyLittleThing Turns Burj Khalifa Pink

Doctors Hospital Takes Action to Preserve Fair Competition After the Cayman Government Grants a Series of Financial Concessions

Maybelline New York Announces Storm Reid As Global Spokesmodel

The Craft Irish Whiskey Co. Sets the Record for the World's Most Expensive Whiskey Collection in Partnership With Fabergé

ZS PRIZE, a healthcare innovation programme, selects top 8 teams for jury evaluation and final winner announcement in April 2021

SUN Mobility and Zyngo partner to offer seamless last-mile delivery

India Nightlife Convention & Awards (INCA) concludes its 5th Edition in Goa

OKExChain welcomes Cosmostation validator node operator among six other partners to its rapidly expanding ecosystem

Voltas introduces the new 2021 range of Voltas Fresh Air Coolers; launches 'Ab Garmi Ke Mazey Lo, Bina Garmi Ke' campaign

Aster MIMS Calicut Offers Free Liver Transplant Surgeries to Children

'The Apprentice: ONE Championship Edition' to Premiere in India tomorrow, March 20th on Republic TV

APML issues pre-alert and guidelines to save innocent citizens from fake websites and fraudsters in packing and moving segment

GC to Increase Vinythai Shares through Delisting Tender Offer, Strengthening Downstream Chemicals Business, and Expanding Its Business in CLMV Market

Flexible workspaces to lease 3 million square feet of space in 2021: Colliers

RateGain Ranks in Deloitte Technology Fast50 For The Fifth Time

First Advantage launches Vendor Screening Solution

NMIMS Hyderabad Invites Applications for Common Entrance Tests - NMIMS- NPAT, NMIMS-CET and NMIMS-LAT - for Commerce, Pharmacy, & Law Programs

IAS Extends its Leadership in Brand Safety and Ad Fraud Protection with TAG Recertification

CITIC Networks Becomes Big Data Exchange (BDx) Connectivity Partner in Nanjing Data Center

ApiJect Systems, Corp., Announces Appointment of Global Branding Leader, Craig Cohon as Chief Strategy Officer

Encore® Launches Hybrid+, Setting A Global Standard For Hybrid Meeting & Event Experiences

New Report Discusses IT/OT Convergence for Telcos

SDI Adds Acteev Protect™ Masks to Portfolio of PPE As-a-Service(SM)

The 129th Canton Fair Prepares for a Virtual Return from April 15-24, 2021

Hitachi launches new range of Room Air Conditioners for the new-age consumers: 'One for everyone'

Five Business Strategies to Ensure Environment Safety and Leverage eWaste Management

Huawei Recognized as a 2021 Gartner Peer Insights Customers' Choice for WAN Edge Infrastructure

"Charm of Jiangsu" celebrated the 2021 Chinese New Year with overseas fans online

GameAnalytics Joins Huawei Ecosystem as the Latest Platform Partner

Frost & Sullivan's India Manufacturing Excellence Awards 2021 to Honor Future-Ready Factories

Adani Green Energy raises USD 1.35 billion in one of Asia's largest project financing deals

Reliance Securities named as India's 10 most promising share trading platforms of 2020

QuerySurge is Now Available in the Microsoft Azure Marketplace

XCMG Celebrates International Day of Happiness, Champions Employee Wellbeing with its Upgraded Total Health Program

ZestMoney Ranked Second Fastest Growing Technology Company in Deloitte Technology Fast 50 India 2020

Firescore Interactive to launch the hyper-casual gaming hub 'CrazyHubs India' in partnership with CrazyLabs

Technical clothing requirements for armed forces likely to be included in negative import list; keen to procure indigenised techno textiles: General Bipin Rawat

Frost & Sullivan Identifies the Top 5 Growth Opportunities in the Next-Generation Connected Car Industry

Trimble Announces Release of Tekla 2021 Structural BIM Software Solutions

Nespresso invests CHF 117 million in the expansion of its Avenches production center to meet growing consumer demand

FDI - Dental disaster: One year after first lockdowns dentists around the world confront the consequences of the COVID-19 pandemic on people's oral health: higher incidence of tooth decay and more advanced gum disease

Aeijaz Sodawala, CEO eZee Technosys gives an industry insider view-point on the Google Free Booking Link Program

Skootr Launches Skootr FinSave, A New Company To Meet Growing Demand For Financial Services In The Office Segment

LYRA last-mile connectivity solution for rural India

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
House arrest can be ordered on basis of ...
BJP trying to sneak in through backdoor ...
Delhi HC grants anticipatory bail to jou...
Uttarakhand: No deaths reported in Kainc...
Rajasthan to float global tender to buy ...
Serum Institute CEO promised to deliver ...
More...    
 
 Top Stories
Norway excludes AstraZeneca from va... 
Campaign against Hamas only beginni... 
COVID-19 surveillance teams deploye... 
NAV Backoffice donates medical supp... 
COVID-19: Oxygen shortage costs 14 ... 
IAF airlifts 3 cryogenic oxygen con... 
China exploited pandemic to promote... 
Woscher: Leading car accessory bran...